Dr Jacek Kopec and colleagues from Canada compared health-related quality of life, symptoms, and convenience of care in stage II/III colon cancer.
The research team evaluated patients with carcinoma of the colon who received oral uracil with ftorafur plus leucovorin.
Patients receiving standard intravenous fluorouracil plus leucovorin as adjuvant chemotherapy were also assessed.
The researchers measured health-related quality of life with the Functional Assessment of Cancer Therapy-Colorectal questionnaire.
In addition, the team used the Short Form-36 Vitality Scale.
|Patients perceive uracil with ftorafur and leucovorin as more convenient|
|Journal of Clinical Oncology|
The Quality of Life Rating Scale was used at baseline, once during chemotherapy, and at 1 year.
The team also used the Symptom Distress Scale, and a treatment-specific Symptom Checklist to assess symptoms.
A modified Burden of Care form was used to assess convenience of care at baseline, on day 1 of each treatment cycle, and at 1 year.
The researchers applied repeated measures analyses controlling for demographic variables, and baseline scores for statistical comparisons.
The team accrued 1608 patients, of which 803 were in the fluorouracil arm and 805 in the uracil with ftorafur arm.
There were no differences between the arms in overall Functional Assessment of Cancer Therapy-Colorectal scores or its subscale scores.
The research team noted no differences in the Quality of Life Rating Scale scores.
The researchers found that patients taking uracil with ftorafur reported substantially higher convenience of care.
The team observed significant but small differences for Short Form-36 Vitality Scale, favoring fluorouracil.
The researchers also identified significant differences for Symptom Distress Scale and Symptom Checklist, both favoring uracil with ftorafur.
Dr Kopec's team concludes, “Patients perceive adjuvant treatment with uracil with ftorafur and leucovorin as more convenient than standard intravenous treatment with fluorouracil plus leucovorin.”
“Both regimens are well tolerated and do not differ in their impact on health-related quality of life.”